Anti-N-methyl-D-Aspartate Receptor Encephalitis Mimicking Sporadic Creutzfeldt–Jakob Disease
| Autor: | Xueping Chen, Huifang Shang, Liyan Chen, Lan Wang, Jing Yang, Jiao Liu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Movement disorders
genetic structures anti-NMDAR encephalitis sporadic Creutzfeldt-Jakob disease Case Report Disease lcsh:RC346-429 03 medical and health sciences 0302 clinical medicine mental disorders differential diagnosis medicine 030212 general & internal medicine Receptor 14-3-3 protein lcsh:Neurology. Diseases of the nervous system biology business.industry medicine.disease nervous system Neurology Immunology biology.protein NMDA receptor immunomodulatory therapy Neurology (clinical) Differential diagnosis Antibody medicine.symptom business psychological phenomena and processes 030217 neurology & neurosurgery Encephalitis |
| Zdroj: | Frontiers in Neurology, Vol 11 (2020) Frontiers in Neurology |
| ISSN: | 1664-2295 |
| DOI: | 10.3389/fneur.2020.593680 |
| Popis: | Objectives: Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis and sporadic Creutzfeldt–Jakob disease (sCJD) share similar clinical features. Here, we present two unusual cases of anti-NMDAR encephalitis who were misdiagnosed as sCJD at first.Methods: We described two patients' clinical manifestations, as well as the string of symptomatological evolution, treatments, and follow-up results.Results: Our patients presented with rapidly progressive dementia, memory problems, psychiatric symptoms, and movement disorders, and we considered all these symptoms as a presenting feature of sCJD at first, but the cerebrospinal fluid examination showed positive results for both the 14-3-3 protein and antibodies against NMDAR. Immunomodulatory treatment led to a resolution of these deficits, and both of them remained in remission after treatment.Conclusion: Anti-NMDAR encephalitis can present with rapidly progressive cognitive decline, and sometimes laboratory investigations can be misleading. The examination for the presence of NMDAR antibodies is necessary, even with the presence of 14-3-3 protein. Early immunomodulatory therapy should be considered, especially for patients with high titers of NMDAR antibodies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|